Bile Duct Cancer

Providing you the best range of pemigatinib 4.5 mg tablets with effective & timely delivery.

Pemigatinib 4.5 mg Tablets

Request Callback

₹ 4265 / Box Get Latest Price

Product Brochure
Brand NameLuciPem
FormTablet
Storage Condition20 DegreeC to 25 DegreeC
Prescription/Non prescriptionPrescription
CompositionPemigatinib
Strength4.5 mg
Packaging Size14 Tablets
ManufacturerLucius Pharmaceuticals, Laos
Packaging TypeBox
TreatmentA rare cancer of the bile ducts
Shelf Life24 Months
Manufacturing UnitLaos

Minimum order quantity: 10 Box

Lucipem 4.5mg is a targeted cancer therapy that contains Pemigatinib, a selective inhibitor of fibroblast growth factor receptors (FGFR). Developed for precision oncology, it is primarily used in the treatment of cholangiocarcinoma (a rare cancer of the bile ducts) and other tumors associated with FGFR genetic alterations. Lucipem represents a significant advancement in personalized cancer treatment by offering an option based on specific genetic markers.

What is Lucipem 4.5mg (Pemigatinib)?

Lucipem 4.5mg is an oral anticancer drug formulated with Pemigatinib, a small molecule kinase inhibitor. It is marketed for patients whose cancers exhibit FGFR2 fusions or rearrangements. Approved by regulatory bodies such as the US FDA under accelerated pathways, Pemigatinib is used when the cancer is unresectable (cannot be removed by surgery) or has metastasized (spread to other organs).

How it Works / Mechanism of Action

Pemigatinib works by inhibiting the activity of FGFR1, FGFR2, and FGFR3—proteins that play a vital role in cell growth, survival, and differentiation.Cancer and unchecked cell proliferation can result from FGFR gene fusions or rearrangements. By selectively binding to these receptors, Pemigatinib blocks downstream signaling pathways such as MAPK, PI3K-AKT, and PLCγ, which are responsible for tumor growth. This inhibition suppresses tumor progression and induces cell death in cancer cells with FGFR abnormalities.

How to Use / Indications

Lucipem 4.5mg is indicated for:

  • FGFR2 fusion or rearrangement in an incurable locally progressed or metastatic cholangiocarcinoma, as verified by a diagnostic test approved by the FDA.

  • It is also being studied and used off-label in urothelial carcinoma, glioblastoma, and other rare FGFR-driven tumors in clinical settings.

How to Take / Dosage

Standard Dosage:

  • The recommended dose is 13.5 mg once daily for 14 days, followed by 7 days off in a 21-day cycle.

  • Lucipem 4.5mg tablets are usually taken in a divided dose (e.g., 3 tablets) to reach 13.5 mg per day.

Administration Tips:

  • Take it at the same time every day.

  • Can be taken with or without food.

  • Swallow tablets whole with water. Do not crush or split.

  • Avoid taking with grapefruit or grapefruit juice (may alter drug metabolism).

Side EffectsCommon Side Effects:
  • Hyperphosphatemia

  • Nail changes

  • Dry mouth

  • Fatigue

  • Hair thinning or loss

  • Diarrhea or constipation

  • Loss of appetite

Serious Side Effects:
  • Eye disorders (e.g., retinal detachment, blurred vision)

  • Electrolyte imbalances (especially phosphate, calcium)

  • Kidney or liver dysfunction

  • Stomatitis (inflammation of the mouth)

  • Non-healing mouth ulcers

  • Skin rashes or hand-foot syndrome

Storage
  • Store Lucipem 4.5mg tablets at room temperature (20°C to 25°C).

  • Protect from moisture and direct light.

  • Keep it in the original packaging until use.

  • Keep out of reach of children.

  • Do not use expired medication.

Benefits

Lucipem offers numerous benefits, especially for patients with no other targeted options:

  • Precision Medicine

  • Oral Administration

  • Disease Control

  • Tolerability

  • Hope in Rare Cancers

X

Contact Us

Tushar Ghanshyambhai Kalathiya (CEO)
Leaf Pharma
Ground Floor Plot No-19 Opp. Govindaji Hall, Dabholi Road, OPP. GOVINDAJI HALL, Surat - 395004, Gujarat, India

Get Directions
Send Email
Share: